Terms: = Prostate cancer AND EP300, ENSG00000100393, 2033, RP1-85F18_1, p300
216 results:
1. ep300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells.
Huttunen J; Aaltonen N; Helminen L; Rilla K; Paakinaho V
Cell Mol Life Sci; 2024 Apr; 81(1):160. PubMed ID: 38564048
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced prostate cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract] [Full Text] [Related]
3. CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of prostate cancer and Beyond.
Hu J; Xu Y
J Med Chem; 2024 Apr; 67(7):5272-5274. PubMed ID: 38517344
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
[TBL] [Abstract] [Full Text] [Related]
5. Androgen receptor cofactors: A potential role in understanding prostate cancer.
Li X; Xiong H; Mou X; Huang C; Thomas ER; Yu W; Jiang Y; Chen Y
Biomed Pharmacother; 2024 Apr; 173():116338. PubMed ID: 38417290
[TBL] [Abstract] [Full Text] [Related]
6. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
[TBL] [Abstract] [Full Text] [Related]
7. Androgen Receptor-Interacting Proteins in prostate cancer Development and Therapy Resistance.
Culig Z; Puhr M
Am J Pathol; 2024 Mar; 194(3):324-334. PubMed ID: 38104650
[TBL] [Abstract] [Full Text] [Related]
8. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.
Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
[TBL] [Abstract] [Full Text] [Related]
9. Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens.
Lyles RDZ; Martinez MJ; Sherman B; Schürer S; Burnstein KL
PLoS One; 2023; 18(10):e0287126. PubMed ID: 37815978
[TBL] [Abstract] [Full Text] [Related]
10. HIRA-mediated loading of histone variant H3.3 controls androgen-induced transcription by regulation of AR/BRD4 complex assembly at enhancers.
Morozov VM; Riva A; Sarwar S; Kim WJ; Li J; Zhou L; Licht JD; Daaka Y; Ishov AM
Nucleic Acids Res; 2023 Oct; 51(19):10194-10217. PubMed ID: 37638746
[TBL] [Abstract] [Full Text] [Related]
11. p300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC.
Zhang M; Kan D; Zhang B; Chen X; Wang C; Chen S; Gao W; Yang Z; Li Y; Chen Y; Zhu S; Wen S; Niu Y; Shang Z
J Exp Clin Cancer Res; 2023 Aug; 42(1):215. PubMed ID: 37599359
[TBL] [Abstract] [Full Text] [Related]
12. Reevaluation of bromodomain ligands targeting BAZ2A.
Cazzanelli G; Vedove AD; Parolin E; D'Agostino VG; Unzue A; Nevado C; Caflisch A; Lolli G
Protein Sci; 2023 Sep; 32(9):e4752. PubMed ID: 37574751
[TBL] [Abstract] [Full Text] [Related]
13. Androgen Receptor Variants Confer Castration Resistance in prostate cancer by Counteracting Antiandrogen-Induced Ferroptosis.
Sun R; Yan B; Li H; Ding D; Wang L; Pang J; Ye D; Huang H
Cancer Res; 2023 Oct; 83(19):3192-3204. PubMed ID: 37527336
[TBL] [Abstract] [Full Text] [Related]
14. Unravelling the Role of p300 and TMPRSS2 in prostate cancer: A Literature Review.
Gioukaki C; Georgiou A; Gkaralea LE; Kroupis C; Lazaris AC; Alamanis C; Thomopoulou GE
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511059
[TBL] [Abstract] [Full Text] [Related]
15. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
Li X; Wang Y; Deng S; Zhu G; Wang C; Johnson NA; Zhang Z; Tirado CR; Xu Y; Metang LA; Gonzalez J; Mukherji A; Ye J; Yang Y; Peng W; Tang Y; Hofstad M; Xie Z; Yoon H; Chen L; Liu X; Chen S; Zhu H; Strand D; Liang H; Raj G; He HH; Mendell JT; Li B; Wang T; Mu P
Cancer Cell; 2023 Aug; 41(8):1427-1449.e12. PubMed ID: 37478850
[TBL] [Abstract] [Full Text] [Related]
16. Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells.
Filon M; Yang B; Purohit TA; Schehr J; Singh A; Bigarella M; Lewis P; Denu J; Lang J; Jarrard DF
Oncotarget; 2023 Jul; 14():738-746. PubMed ID: 37477521
[TBL] [Abstract] [Full Text] [Related]
17. Overexpression of miR-17-5p may negatively impact p300/CBP factor-associated inflammation in a hypercholesterolemic advanced prostate cancer model.
Pimenta R; Camargo JA; Gonçalves GL; Ghazarian V; Candido P; Guimarães VR; Romão P; Chiovatto C; da Silva KS; Dos Santos GA; Silva IA; Nahas WC; Leite KR; Pessoa AFM; Viana NI; Reis ST
Mol Biol Rep; 2023 Sep; 50(9):7333-7345. PubMed ID: 37439896
[TBL] [Abstract] [Full Text] [Related]
18. YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6.
Chen S; Lu K; Hou Y; You Z; Shu C; Wei X; Wu T; Shi N; Zhang G; Wu J; Chen S; Zhang L; Li W; Zhang D; Ju S; Chen M; Xu B
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094986
[TBL] [Abstract] [Full Text] [Related]
19. Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer.
Rezaeian AH; Phan LM; Zhou X; Wei W; Inuzuka H
Neoplasia; 2023 Apr; 38():100890. PubMed ID: 36871351
[TBL] [Abstract] [Full Text] [Related]
20. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast cancer.
Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
[TBL] [Abstract] [Full Text] [Related]
[Next]
